EMA restructures organization.
RELATED ARTICLES
The European Medicines Agency is moving forward with plans to restructure the organization. EMA’s management team began transitioning to a new structure on August 1, 2013. The Agency expects to complete the full transition period for the new structure and the revised operating processes in 2014. In the meantime, it will ensure continuity of operations for the evaluation and supervision of medicines.
The agency is creating four new divisions that will support and focus on research and development; evaluate lifecycle management; develop procedures for management and business data; and inspections and pharmacovigilance.
EMA will announce details of the new structure of the organization in September 2013.
Source: European Medicines Agency
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/08/news_detail_001868.jsp&mid=WC0b01ac058004d5c1
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.